Age as prognostic factor in patients with osteosarcoma

Bone

Volumn 49, Issue 6, 2011, Pages 1173-1177

  Hagleitner, Melanie M ^a   Hoogerbrugge, Peter M ^a   van der Graaf, Winette T A ^a   Flucke, Uta ^a   Schreuder, H W Bart ^a   te Loo, D Maroeska W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Age; Epidemiology; Osteosarcoma; Outcome; Prognostic factors

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONSET AGE; OSTEOSARCOMA; OTOTOXICITY; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGING; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; OSTEOSARCOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; YOUNG ADULT;

EID: 81355148859     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.08.014     Document Type: Article

References (31)

1. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115:1531-1543.
2. Dahlin D.C. Osteosarcoma of bone and a consideration of prognostic variables. Cancer Treat Rep 1978, 63:189-192.
3. Cortes E.P., Holland J.F., Wang J.J., et al. Doxorubicin in disseminated osteosarcoma. JAMA 1972, 221:1132-1138.
4. Jaffe N., Paed D., Farber S., et al. Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy. Cancer 1973, 31:1367-1373.
5. Smith M.A., Ungerleider R.S., Horowitz M.E., et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic osteosarcoma and Ewing's sarcoma. J Natl Cancer Inst 2001, 83:1460-1470.
6. Lewis I.J., Nooij M.A., Whelan J., et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007, 99:112-128.
7. Graf N., Winkler K., Betlemovic M., et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 1994, 12:1443-1451.
8. Delepine N., Delepine G., Bacci G., et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 1996, 78:2127-2135.
9. Goldsby R., Burke C., Nagarajan R., et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort. Cancer 2008, 113:2597-2604.
10. Mansky P., Arai A., Stratton P., et al. Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 2007, 48:192-199.
11. Pui C.H., Evans W.E. Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605-615.
12. Razzouk B.I., Estey E., Pound S., et al. Impact of age on outcome of pediatric acute myeloid leukemia. Cancer 2006, 106:2495-2502.
13. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma group protocols. J Clin Oncol 2002, 20:776-790.
14. Kager L., Zoubek A., Potschger U., et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2003, 21:2011-2018.
15. Mankin H.J., Hornicek F.J., Rosenberg A.E., et al. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004, 429:286-291.
16. Lee J.A., Kim M.S., Kim D.H., et al. Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. Pediatr Blood Cancer 2009, 52:340-345.
17. Fuchs N., Bielack S.S., Epler D., et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998, 9:893-899.
18. Ferrari S., Bertoni F., Mercuri M., et al. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol 2001, 12:1145-1150.
19. Meyers P.A., Heller G., Healey J., et al. Chemotherapy for non-metastatic osteogenic sarcoma. The Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10:5-15.
20. Bacci G., Longhi A., Versari M., et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2005, 106:1154-1161.
21. Boissel N., Auclerc M.-F., Lhéritier V., et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774-780.
22. Rosen G., Caparros B., Huvos A.G., et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperatieve adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49:1221-1230.
23. Enneking W.F., Spanier M.D., Goodman M.A. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980, 153:106-120.
24. Kaplan E.L., Meier P. Nonparametric observations from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
25. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-220.
26. Bieling P., Rehan N., Winkler P., et al. Tumour size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996, 14:848-858.
27. Longhi A., Errani C., Gonzales-Arabio D., et al. Osteosarcoma in patients older than 65years. J Clin Oncol 2008, 26:5368-5373.
28. Bacci G., Longhi A., Fagioli F., et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27year experience at Rizzoli Institute, Italy. Eur J Cancer 2005, 41:2836-2845.
29. Hartig M.T., Lally K.P., Andrassy R.J., et al. Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 2010, 4:561-570.
30. Rosen G., Marcove R.C., Caparros B., et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979, 43:2168-2177.
31. Bacci G., Ferrari S., Longhi A., et al. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy. Oncol Rep 2003, 10:851-857.